Impaired PRC2 activity promotes transcriptional instability and favors breast tumorigenesis
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Alterations of chromatin modifiers are frequent in cancer, but their functional consequences often remain unclear. Focusing on the Polycomb protein EZH2 that deposits the H3K27me3 (trimethylation of Lys27 of histone H3) mark, we showed that its high expression in solid tumors is a consequence, not a cause, of tumorigenesis. In mouse and human models, EZH2 is dispensable for prostate cancer development and restrains breast tumorigenesis. High EZH2 expression in tumors results from a tight coupling to proliferation to ensure H3K27me3 homeostasis. However, this process malfunctions in breast cancer. Low EZH2 expression relative to proliferation and mutations in Polycomb genes actually indicate poor prognosis and occur in metastases. We show that while altered EZH2 activity consistently modulates a subset of its target genes, it promotes a wider transcriptional instability. Importantly, transcriptional changes that are consequences of EZH2 loss are predominantly irreversible. Our study provides an unexpected understanding of EZH2's contribution to solid tumors with important therapeutic implications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
METABRIC Group, Curtis, C., Shah, S. P., Chin, S.-F., Turashvili, G., Rueda, O. M., Dunning, M. J., Speed, D., Lynch, A. G., Samarajiwa, S., et al. (2012) · Nature · doi:10.1038/nature10983 · Cited by 6,097 · cited 4×
“To address this issue, we used transcriptome/CNV data from the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) (Curtis et al. 2012), which collected information on transcript levels and copy number as well as long-term clinical follow-ups from 2000 breast cancers (Curtis et al. 2012).”
MethodInfluentialThe polycomb group protein EZH2 is involved in progression of prostate cancer
Varambally, S., Dhanasekaran, S. M., Zhou, M., Barrette, T. R., Kumar-Sinha, C., Sanda, M. G., Ghosh, D., Pienta, K. J., Sewalt, R. G. A. B., Otte, A. P., et al. (2002) · Nature · doi:10.1038/nature01075 · Cited by 2,717 · cited 2×
“More relevant to the present work, previous studies reported high levels of EZH2 in carcinomas such as prostate and breast cancer (Varambally et al. 2002; Kleer et al. 2003).”
MethodResultKleer, C. G., Cao, Q., Varambally, S., Shen, R., Ota, I., Tomlins, S. A., Ghosh, D., Sewalt, R. G. A. B., Otte, A. P., Hayes, D. F., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1933744100 · Cited by 1,649 · cited 2×
“More relevant to the present work, previous studies reported high levels of EZH2 in carcinomas such as prostate and breast cancer (Varambally et al. 2002; Kleer et al. 2003).”
BackgroundResultInhibition of PRC2 Activity by a Gain-of-Function H3 Mutation Found in Pediatric Glioblastoma
Lewis, P. W., Müller, M. M., Koletsky, M. S., Cordero, F., Lin, S., Banaszynski, L. A., Garcia, B. A., Muir, T. W., Becher, O. J., & Allis, C. D. (2013) · Science · doi:10.1126/science.1232245 · Cited by 1,345 · cited 1×
“Moreover, in pediatric glioblastomas, point mutations resulting in a change from lysine to methionine at position 27 of histone H3 (H3K27M) have been shown to inhibit PRC2 activity (Lewis et al. 2013), suggesting that disruption of the Polycomb machinery might be a recurring theme in cancers.”
BackgroundEZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer.
Bracken, A. P., Pasini, D., Capra, M., Prosperini, E., Colli, E., & Helin, K. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg542 · Cited by 1,196
Wang, S., Gao, J., Lei, Q., Rozengurt, N., Pritchard, C., Jiao, J., Thomas, G. V., Li, G., Roy-Burman, P., Nelson, P. S., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00215-0 · Cited by 1,109 · cited 2×
“Conditional deletion of this gene in mouse prostates leads to prostate adenocarcinomas with varying degrees of severity (Wang et al. 2003; Ma et al. 2005), presumably due to differences in the genetic background and/or mutant allele used.”
BackgroundKelm, J. M., Timmins, N. E., Brown, C. J., Fussenegger, M., & Nielsen, L. K. (2003) · Biotechnology and Bioengineering · doi:10.1002/bit.10655 · Cited by 934
Bracken, A. P., Kleine-Kohlbrecher, D., Dietrich, N., Pasini, D., Gargiulo, G., Beekman, C., Theilgaard-Mönch, K., Minucci, S., Porse, B. T., Marine, J.-C., et al. (2007) · Genes & Development · doi:10.1101/gad.415507 · Cited by 850 · cited 2×
“Prior studies 2548 GENES & DEVELOPMENT suggest that Ezh2 can control cell proliferation in part through silencing of the Ink4a/Arf and p21 tumor suppressor loci (Bracken et al. 2007; Seward et al. 2013).”
BackgroundEpigenetic expansion of VHL-HIF signal output drives multiorgan metastasis in renal cancer
Vanharanta, S., Shu, W., Brenet, F., Hakimi, A. A., Heguy, A., Viale, A., Reuter, V. E., Hsieh, J. J.-D., Scandura, J. M., & Massagué, J. (2013) · Nature Medicine · doi:10.1038/nm.3029 · Cited by 215 · cited 2×
“2012) and in renal cancer (Vanharanta et al. 2013).”
BackgroundWoodhouse, S., Pugazhendhi, D., Brien, P., & Pell, J. M. (2013) · Journal of Cell Science · doi:10.1242/jcs.114843 · Cited by 84 · cited 2×
“However, disruption of PRC2 only results in the detectable up-regulation of a minority of tissue-specific genomic targets (Fig. 5A; Ezhkova et al. 2009; Woodhouse et al. 2013).”
Background
Cited by
Epigenetic modulators, modifiers and mediators in cancer aetiology and progression
Feinberg, A. P., Koldobskiy, M. A., & Göndör, A. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.13 · Cited by 841
Maintaining cell identity: PRC2-mediated regulation of transcription and cancer
Comet, I., Riising, E. M., Leblanc, B., & Helin, K. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.83 · Cited by 432
Mohammed, H., Hernando-Herraez, I., Savino, A., Scialdone, A., Macaulay, I., Mulas, C., Chandra, T., Voet, T., Dean, W., Nichols, J., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.07.009 · Cited by 340
So, J. Y., Ohm, J., Lipkowitz, S., & Yang, L. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108253 · Cited by 256
CCAT 1: a pivotal oncogenic long non‐coding RNA in human cancers
Xin, Y., Li, Z., Shen, J., Chan, M. T. V., & Wu, W. K. K. (2016) · Cell Proliferation · doi:10.1111/cpr.12252 · Cited by 227
Dangerous liaisons: interplay between SWI/SNF, NuRD, and Polycomb in chromatin regulation and cancer
Bracken, A. P., Brien, G. L., & Verrijzer, C. P. (2019) · Genes & Development · doi:10.1101/gad.326066.119 · Cited by 192
“However, elevatedEZH2 expression is not considered to lead to deregulation of H3K27 methylations, because the stoichiometry of the core PRC2 complex would require correspondingly high levels of the EED and SUZ12 subunits (Wassef et al. 2015).”
BackgroundTug of war: adding and removing histone lysine methylation in Arabidopsis
Xiao, J., Lee, U.-S., & Wagner, D. (2016) · Current Opinion in Plant Biology · doi:10.1016/j.pbi.2016.08.002 · Cited by 174
Emerging roles for Polycomb proteins in cancer
Pasini, D., & Di Croce, L. (2016) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2016.03.013 · Cited by 133
Mahara, S., Lee, P. L., Feng, M., Tergaonkar, V., Chng, W. J., & Yu, Q. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1602079113 · Cited by 87
Metadata
- Authors
- Wassef, M., Rodilla, V., Teissandier, A., Zeitouni, B., Gruel, N., Sadacca, B., Irondelle, M., Charruel, M., Ducos, B., Michaud, A., Caron, M., Marangoni, E., Chavrier, P., Le Tourneau, C., Kamal, M., Pasmant, E., Vidaud, M., Servant, N., Reyal, F., Meseure, D., Vincent-Salomon, A., Fre, S., & Margueron, R.
- Venue
- Genes & Development
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2015-12-04
- Volume
- 29
- Issue
- 24
- Pages
- 2547-2562
- ISSN
- 0890-9369 (ISSN-L)
- 1549-5477
- OpenAlex
- W2181751096
- Cited by
- 87
- References
- 10
- Type
- posted content
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.